The new, versatile platform offers two configurations, a combined console (VCS) as well as a standalone cataract system (CS). This platform is designed to deliver superior efficiency for vitreoretinal ...

The new, versatile platform offers two configurations, a combined console (VCS) as well as a standalone cataract system (CS). This platform is designed to deliver superior efficiency for vitreoretinal ...

Collaboration will deliver innovative AI-powered pathology tools and quality control enhancements to accelerate clinical trials and biomarker discovery. Precision for Medicine, a leading provider of ...

Continue ReadingSecond Phase of ADVANTAGE AF study of FARAPULSE ™ Pulsed Field Ablation System Meets Primary Safety and Efficacy Endpoints ...

Collaboration will deliver innovative AI-powered pathology tools and quality control enhancements to accelerate clinical trials and biomarker discovery. Continue ReadingPrecision for Medicine and ...

The Series B-1 warrants will have an exercise price of $0.85 per share, will be immediately exercisable and will expire 5 years from issuance. The Series B-2 warrants will have an exercise price of $0 ...

Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of the ADVANTAGE AF clinical trial evaluating the use of the FARAPULSE™ ...